This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Quality of Life  • Neoplasms  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Marie-France Demierre, MD, FRCPC; Amy Tien, MD; Donald Miller, ScD

Arch Dermatol. 2005;141:325-330.

Objective  To measure and evaluate the health-related quality of life (HRQOL) in patients with cutaneous T-cell lymphoma (CTCL), a visible cutaneous malignancy that may have a profound effect on patients’ lives.

Design  Monocenter, cross-sectional study.

Setting  The Skin Oncology Program, Department of Dermatology, and the Photopheresis Unit of Boston Medical Center.

Patients  A total of 22 adult patients with confirmed CTCL.

Main Outcome Measures  (1) Evaluation of general oncologic and skin disease–specific HRQOL using, respectively, the Functional Assessment of Cancer Therapy–General (FACT-G) and Skindex-29 profiles; (2) assessment of HRQOL association with disease stage (early stage, IA-IIA; late stage, IIB-IVB).

Results  Patients with more advanced CTCL stages reported more effects on general health (FACT-G), particularly in the physical, emotional, and functional domains (P<.05). Patients with early-stage CTCL reported better skin-specific HRQOL overall (Skindex-29; P = .002) and for each specific domain than did patients with late-stage disease. The Skindex-29 scales had high internal consistency, and the confirmatory factor structure was similar to that of previous studies.

Conclusions  The HRQOL of patients with CTCL can be evaluated using the Skindex-29 and FACT-G instruments. Patients with more advanced stages of CTCL had lower HRQOL scores.

Author Affiliations: Department of Dermatology, Boston University School of Medicine (Drs Demierre and Miller); Department of Medicine, Boston University Medical Center (Dr Tien); and Boston University School of Public Health (Dr Miller), Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Measuring HRQOL in Patients With Cutaneous T-Cell Lymphoma Undergoing Therapy With Oral Bexarotene and Extracorporeal Photopheresis
Demierre et al.
Arch Dermatol 2007;143:659-661.
FULL TEXT  

Palliative Care in Patients With Primary Cutaneous Lymphoma: Symptom Burden and Characteristics of Hospital Palliative Care Team Input
LeBon et al.
Arch Dermatol 2007;143:423-424.
FULL TEXT